F. Hoffmann-La Roche AG


About Roche

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the eleventh consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2019 employed about 98,000 people worldwide. In 2019, Roche invested CHF 11.7 billion in R&D and posted sales of CHF 61.5 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

Roche retains sole responsibility for content © 2020 F. Hoffmann-La Roche AG. All trademarks used or mentioned in this release are protected by law.

1 August 2019 - 31 July 2020

Region: Global
Subject/journal group: All

The table to the right includes counts of all research outputs for F. Hoffmann-La Roche AG published between 1 August 2019 - 31 July 2020 which are tracked by the Nature Index.

Hover over the donut graph to view the FC output for each subject. Below, the same research outputs are grouped by subject. Click on the subject to drill-down into a list of articles organized by journal, and then by title.

Note: Articles may be assigned to more than one subject area.

Count Share
153 60.62

Outputs by subject (Share)

Subject Count Share
Life Sciences 126 42.50
Chemistry 33 19.53
15 11.95
1 0.83
1 0.20
1 0.17
1 0.08
3 0.34
3 1.21
6 4.19
1 0.56
1 0
Physical Sciences 3 0.75
Earth & Environmental Sciences 1 0.50

Highlight of the month

Dying tumour cells promote anti-cancer immunity

© Stocktrek Images/Getty

© Stocktrek Images/Getty

Blocking the clearance of dying tumour cells can help bolster the cancer-killing response of the immune system.

That’s according to a mouse study by scientists at the Roche subsidiary Genentech. They generated an antibody drug directed against MerTK, a protein found on the surface of cell-devouring immune cells called macrophages.

Macrophages normally use MerTK to detect and remove dying cells before they release cellular contents can stimulate inflammation. Timely removal of these ailing cells prevents inflammation and contributes to the immune tolerance of tumours.

But the MerTK-targeted antibody gums up this process. With the dying cells left in place, cell-free DNA spills into the tumour microenvironment, which leads to an enhanced adaptive immune response.

In tumour-bearing mice, MerTK inhibition enhanced the effectiveness of treatment with other immunotherapy drugs. Several anti-MerTK drug therapies are now in early clinical testing.

Supported content

  1. Immunity 52, 357–373.e9 (2020). doi: 10.1016/j.immuni.2020.01.014

View the article on the Nature Index

See more research highlights from F. Hoffmann-La Roche AG

More research highlights from F. Hoffmann-La Roche AG

1 August 2019 - 31 July 2020

International vs. domestic collaboration by Share

  • 7.84% Domestic
  • 92.16% International

Note: Hover over the graph to view the percentage of collaboration.

Note: Collaboration is determined by the fractional count (Share), which is listed in parentheses.

Affiliated joint institutions and consortia

Return to institution outputs